Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Alnylam Pharmaceuticals stock in Canada | $141.99

Own Alnylam Pharmaceuticals shares in just a few minutes.

Alnylam Pharmaceuticals, Inc
-$0.81 (-0.45%)

Alnylam Pharmaceuticals is a biotechnology business based in the US. Alnylam Pharmaceuticals stocks (ALNY.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $166.5 – an increase of 1.86% over the previous week. Alnylam Pharmaceuticals employs 1,453 staff and has a trailing 12-month revenue of around $570.9 million.

How to buy Alnylam Pharmaceuticals stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: ALNY in this case.
  5. Research Alnylam Pharmaceuticals stocks. The platform should provide the latest information available.
  6. Buy your Alnylam Pharmaceuticals stocks. It's that simple.

How has Coronavirus impacted Alnylam Pharmaceuticals's stock price?

Since the stock market crash in March caused by coronavirus, Alnylam Pharmaceuticals's stock price has had significant positive movement.

Its last market close was $141.99, which is 7.72% up on its pre-crash value of $131.03 and 67.11% up on the lowest point reached during the March crash when the stocks fell as low as $84.97.

If you had bought $1,000 worth of Alnylam Pharmaceuticals stocks at the start of February 2020, those stocks would have been worth $863.80 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,238.15.

Alnylam Pharmaceuticals stock price

Use our graph to track the performance of ALNY stocks over time.

Alnylam Pharmaceuticals stocks at a glance

Information last updated 2021-07-30.
Latest market close$141.99
52-week range$119.29 - $184.45
50-day moving average $173.4662
200-day moving average $152.8093
Wall St. target price$174.78
Dividend yield N/A (0%)
Earnings per share (TTM) $-8.254

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Alnylam Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Alnylam Pharmaceuticals price performance over time

Historical closes compared with the last close of $141.99

1 month (2021-07-02) -17.17%
3 months (2021-04-30) 0.96%

Alnylam Pharmaceuticals financials

Revenue TTM USD$570.9 million
Gross profit TTM USD$414.8 million
Return on assets TTM -18.17%
Return on equity TTM -77.01%
Profit margin -153.49%
Book value $7.895
Market capitalisation USD$21.4 billion

TTM: trailing 12 months

How to short and sell Alnylam Pharmaceuticals stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "ALNY.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 4.2 million Alnylam Pharmaceuticals stocks held short by investors – that's known as Alnylam Pharmaceuticals's "short interest". This figure is 2.4% down from 4.3 million last month.

There are a few different ways that this level of interest in shorting Alnylam Pharmaceuticals stocks can be evaluated.

Alnylam Pharmaceuticals's "short interest ratio" (SIR)

Alnylam Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Alnylam Pharmaceuticals stocks currently shorted divided by the average quantity of Alnylam Pharmaceuticals stocks traded daily (recently around 757982.58527828). Alnylam Pharmaceuticals's SIR currently stands at 5.57. In other words for every 100,000 Alnylam Pharmaceuticals stocks traded daily on the market, roughly 5570 stocks are currently held short.

However Alnylam Pharmaceuticals's short interest can also be evaluated against the total number of Alnylam Pharmaceuticals stocks, or, against the total number of tradable Alnylam Pharmaceuticals stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alnylam Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding stocks (for every 100,000 Alnylam Pharmaceuticals stocks in existence, roughly 40 stocks are currently held short) or 0.0361% of the tradable stocks (for every 100,000 tradable Alnylam Pharmaceuticals stocks, roughly 36 stocks are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against Alnylam Pharmaceuticals.

Find out more about how you can short Alnylam Pharmaceuticals stock.

Alnylam Pharmaceuticals stock dividends

We're not expecting Alnylam Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Alnylam Pharmaceuticals stock price volatility

Over the last 12 months, Alnylam Pharmaceuticals's stocks have ranged in value from as little as $119.29 up to $184.45. A popular way to gauge a stock's volatility is its "beta".

ALNY.US volatility(beta: 1.23)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alnylam Pharmaceuticals's is 1.228. This would suggest that Alnylam Pharmaceuticals's stocks are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Alnylam Pharmaceuticals overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG to develop, manufacture, and commercialize RNAi therapeutics for the treatment of proprotein convertase subtilisin/kexin type 9, hypercholesterolemia, and other human diseases; with Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics to treat SARS-CoV-2, the virus that causes the disease COVID-19; Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease; and with Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Stocks similar to Alnylam Pharmaceuticals

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site